Cargando…
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
BACKGROUND: Tyrosine kinase inhibitors (TKIs) have dramatically changed the prognosis of patients with chronic myeloid leukemia (CML). They have a distinct toxicity profile that includes glycometabolic alterations: i.e. diabetes mellitus (DM), impaired fasting glucose (IFG), and the metabolic syndro...
Autores principales: | Iurlo, Alessandra, Orsi, Emanuela, Cattaneo, Daniele, Resi, Veronica, Bucelli, Cristina, Orofino, Nicola, Sciumè, Mariarita, Elena, Chiara, Grancini, Valeria, Consonni, Dario, Orlandi, Ester Maria, Cortelezzi, Agostino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741815/ https://www.ncbi.nlm.nih.gov/pubmed/26376678 |
Ejemplares similares
-
An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review
por: Orofino, Nicola, et al.
Publicado: (2017) -
Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study
por: Fracchiolla, Nicola Stefano, et al.
Publicado: (2019) -
Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
por: Iurlo, Alessandra, et al.
Publicado: (2021) -
Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022) -
Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality
por: Fattizzo, Bruno, et al.
Publicado: (2020)